Rebound of anti-topoisomerase I antibody titres after plasma exchange.

Hoogen, F.H. van den; Boerbooms, A M; Putte, L B van de; Verheijen, R.; Venrooij, WJ van; Croockewit, Alexandra J.

doi:10.1136/ard.52.3.246

Cited by 3 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 12 of the 19 CRs included in this study, 41 , 42 , 44 , 46 , 48 , 50 , 52 – 57 TPE was used to treat an acute or, in some cases, critical medical situation such as SRC. Typically, these studies look at the effects of TPE over a short period of time (a few weeks or months); TPE was discontinued once the acute situation resolved or improved.…”

Section: Resultsmentioning

confidence: 99%

Therapeutic plasma exchange for the treatment of systemic sclerosis: A comprehensive review and analysis

Harris

Meiselman

Moriarty

et al. 2018

Journal of Scleroderma and Related Disorders

View full text Add to dashboard Cite

Background: Therapeutic plasma exchange has been tried as a treatment approach for systemic sclerosis since 1978 based on the rationale that some circulating factor is involved in disease pathogenesis, for example, autoantibodies or immune complexes, and that removing the potential pathogenic factors could lead to symptom improvement. Based on our impression that clinicians and researchers are largely unaware that a large volume of research has been published about the use of therapeutic plasma exchange as a treatment for systemic sclerosis, we conducted a comprehensive review and analysis of all published research on this topic. Results: We identified 46 relevant articles that met our search criteria, involving a total of 572 patients. Of these, 19 were case studies; the rest ranged from small observational studies to prospective randomized clinical trials. In all but two studies, most patients receiving therapeutic plasma exchange showed improvements in both clinical symptoms and laboratory markers, including significant improvement in Raynaud's symptoms and healing of digital ulceration after three to four weekly treatments. The beneficial effects from even a short course of therapeutic plasma exchange treatments were long-lasting, typically 6 months or longer. Therapeutic plasma exchange was very well tolerated. Adverse events were rare and, in almost all cases, mild and transitory. Conclusion: These results suggest that long-term therapeutic plasma exchange may offer a low-risk way to control and in some cases reverse systemic sclerosis symptoms. The mechanism for the clinical improvements seen from therapeutic plasma exchange in systemic sclerosis patients is unclear. Therefore, additional studies of therapeutic plasma exchange effects in systemic sclerosis appear to be highly desirable.

show abstract

Section: Resultsmentioning

confidence: 99%

Therapeutic plasma exchange for the treatment of systemic sclerosis: A comprehensive review and analysis

Harris

Meiselman

Moriarty

et al. 2018

Journal of Scleroderma and Related Disorders

View full text Add to dashboard Cite

show abstract

Plasma exchange in systemic lupus erythematosus

Euler

Zeuner

Schroeder

1996

Transfusion Science

View full text Add to dashboard Cite

The efficacy of antigen-specific immunoadsorption and rebound of anti-A/B antibodies in ABO-incompatible kidney transplantation

Genberg

Kumlien

Wennberg

et al. 2011

Nephrology Dialysis Transplantation

View full text Add to dashboard Cite

Glycosorb®-ABO IA in combination with rituximab effectively depletes ABabs in most patients, but owing to core-chain-dependent ABabs, Glycosorb®-ABO IA may be less effective than nonspecific techniques for antibody removal in some patients. Rebound before transplantation subsequent to interrupted preconditioning does not hamper a successful ABOi transplantation. Postoperatively, when this protocol for ABOi transplantation is followed, the risk of ABab rebound is small.

show abstract

Rebound of anti-topoisomerase I antibody titres after plasma exchange.

Cited by 3 publications

References 11 publications

Therapeutic plasma exchange for the treatment of systemic sclerosis: A comprehensive review and analysis

Therapeutic plasma exchange for the treatment of systemic sclerosis: A comprehensive review and analysis

Plasma exchange in systemic lupus erythematosus

The efficacy of antigen-specific immunoadsorption and rebound of anti-A/B antibodies in ABO-incompatible kidney transplantation

Contact Info

Product

Resources

About